Targeted and combinational therapy with modified chitosan nanoparticles (NT–, NT+, NTT+, NH+, NHT)
Development Stage: Animal clinical Trials under process
Industry: Cancer treatment
PAK Therapeutics develops and manufactures nanoparticles based on natural polymers contained anti-cancer drugs to treat various cancerous tissues. This product has the capacity to be used for combinational delivery of multiple FDA approved drugs and targeted therapy for cancer treatment.
Polymeric nanoparticles or polymer-coated super-paramagnetic nanoparticles fabricated by PAK Therapeutics are proven to be biocompatible and possess the capacity to load chemotherapy agents and they are proven to be effective in the treatment of cancer with fewer side effects due to increasing the efficacy and bioavailability of chemotherapy agents. The main mission in PAK Therapeutics is to provide nanoparticles with different capacities for cancer treatment. These nanoparticles act as templates and it is possible to load different chemotherapy agents or use them for a different course of treatment based on personalized medical diagnosis results. These nanoparticles can be used for breast, ovarian, colon, stomach, or lung cancer treatment.
This product is capable of loading both hydrophilic and hydrophobic drugs with high efficiency. One of the most prominent features of this product is the simultaneous loading and delivery of multiple drugs with different properties for the combined treatment of cancer, especially breast cancer, and can have a synergistic effect on the treatment and accelerate the recovery process. Also, by simultaneous loading of several medications in nanoparticles, it is possible to reduce the dose of each drug. The release of the drug from these nanoparticles can occur over time and at a slow rate. Due to the presence of folate groups on their chains, these nanoparticles have the ability to actively target cancerous cells that contain folate receptors, including breast cancer, resulting in a reduction in the side effects of chemotherapy. PAK Therapeutics is capable of producing 10,000—100,000 vial of nano-based– formulations per year.